Aptevo Therapeutics Inc. Comprehensive Income
Aptevo Therapeutics Inc. (APVO) reported Comprehensive Income of -$40.45 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-25.
Discontinued › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2020-03-25
- Aptevo Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2019-12-31 was -$8.17M.
- Aptevo Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2019-09-30 was -$6.92M.
- Aptevo Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2019-06-30 was -$13.33M.
- Aptevo Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2019-03-31 was -$12.02M.
- Aptevo Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2019 was -$40.45M.
- Aptevo Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2018 was -$53.58M, a 876.47% decline from fiscal 2017.
- Aptevo Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2017 was $6.90M.
- Aptevo Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$112.45M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$8.17M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$15.10M derived: sum of 2 quarters · filed 2020-03-25 | -$28.43M derived: sum of 3 quarters · filed 2020-03-25 | -$40.45M 10-K · filed 2020-03-25 |
| 2019-09-30 | -$6.92M 10-Q · filed 2019-11-07 | -$20.26M derived: sum of 2 quarters · filed 2019-11-07 | -$32.27M 10-Q · filed 2019-11-07 | -$46.40M derived: sum of 4 quarters · filed 2020-03-25 |
| 2019-06-30 | -$13.33M 10-Q · filed 2019-08-09 | -$25.35M 10-Q · filed 2019-08-09 | -$39.48M derived: sum of 3 quarters · filed 2020-03-25 | -$52.00M derived: sum of 4 quarters · filed 2020-03-25 |
| 2019-03-31 | -$12.02M 10-Q · filed 2019-05-09 | -$26.14M derived: sum of 2 quarters · filed 2020-03-25 | -$38.67M derived: sum of 3 quarters · filed 2020-03-25 | -$51.77M derived: sum of 4 quarters · filed 2020-03-25 |
| 2018-12-31 | -$14.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$26.65M derived: sum of 2 quarters · filed 2020-03-25 | -$39.75M derived: sum of 3 quarters · filed 2020-03-25 | -$53.58M 10-K · filed 2020-03-25 |
| 2018-09-30 | -$12.53M 10-Q · filed 2019-11-07 | -$25.63M derived: sum of 2 quarters · filed 2019-11-07 | -$39.46M 10-Q · filed 2019-11-07 | -$49.28M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | -$13.10M 10-Q · filed 2019-08-09 | -$26.93M 10-Q · filed 2019-08-09 | -$36.75M derived: sum of 3 quarters · filed 2019-08-09 | $1.09M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | -$13.83M 10-Q · filed 2019-05-09 | -$23.65M derived: sum of 2 quarters · filed 2019-05-09 | $14.19M derived: sum of 3 quarters · filed 2019-05-09 | $2.99M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | -$9.82M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $28.02M derived: sum of 2 quarters · filed 2019-03-18 | $16.83M derived: sum of 3 quarters · filed 2019-03-18 | $6.90M 10-K · filed 2019-03-18 |
| 2017-09-30 | $37.84M 10-Q · filed 2018-11-14 | $26.65M derived: sum of 2 quarters · filed 2018-11-14 | $16.72M 10-Q · filed 2018-11-14 | $1.73M derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | -$11.20M 10-Q · filed 2018-08-09 | -$21.15M 10-Q · filed 2018-08-09 | -$36.11M derived: sum of 3 quarters · filed 2018-08-09 | -$107.87M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | -$9.95M 10-Q · filed 2018-05-10 | -$24.91M derived: sum of 2 quarters · filed 2018-05-10 | -$96.67M derived: sum of 3 quarters · filed 2018-05-10 | -$109.51M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | -$14.96M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$86.72M derived: sum of 2 quarters · filed 2018-03-13 | -$99.56M derived: sum of 3 quarters · filed 2018-03-13 | -$112.45M 10-K · filed 2018-03-13 |
| 2016-09-30 | -$71.76M 10-Q · filed 2017-11-13 | -$84.60M derived: sum of 2 quarters · filed 2017-11-13 | -$97.49M 10-Q · filed 2017-11-13 | -$115.38M derived: sum of 4 quarters · filed 2017-11-13 |
| 2016-06-30 | -$12.84M 10-Q · filed 2017-08-10 | -$25.73M 10-Q · filed 2017-08-10 | -$43.63M derived: sum of 3 quarters · filed 2017-08-10 | -$56.30M derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-03-31 | -$12.89M 10-Q · filed 2017-05-12 | -$30.79M derived: sum of 2 quarters · filed 2017-05-12 | -$43.47M derived: sum of 3 quarters · filed 2017-05-12 | |
| 2015-12-31 | -$17.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | -$30.58M derived: sum of 2 quarters · filed 2017-03-31 | -$59.32M 10-K · filed 2017-03-31 | |
| 2015-09-30 | -$12.68M 10-Q · filed 2016-11-14 | -$41.42M 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |